KAZIA THERAPEUTICS

A company developing innovative, high-impact drugs for cancer

Presentation to AusBiotech Invest

Dr James Garner
Chief Executive Officer

Melbourne, Australia 31 October 2019

Forward-Looking Statements

This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of customer acceptance of existing and new products and services and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to sales, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, marketing existing products and services update the forward-looking information contained in this presentation.

Investment Rationale

1. Our lead program, GDC-0084, was **designed by Genentech**, the world's most successful cancer drug developer, and has completed a **successful phase 1 human trial**, showing it to be generally safe and providing signals of efficacy

2. GDC-0084 is a PI3K inhibitor, a well-validated and well-understood class of cancer therapies with **four FDA-approved products**; unique differentiating feature of GDC-0084 is the **ability to cross the blood-brain barrier**

3. **Five clinical trials** of GDC-0084 are currently underway at leading US hospitals, of which four are primarily funded by external parties, covering a broad range of primary and secondary brain cancers to provide **multiple shots on goal**

4. Company is **well-financed**, following a recent institutional placement, with new interim **efficacy data** from lead program expected in November 2019; **pivotal study** for registration expected to commence in 2020

Six ongoing clinical trials across two assets, lead program covers full range of brain cancers

GDC-0084

Primary Brain Cancer
(brain cancer that begins in the brain)

Glioblastoma
Most common and most aggressive brain tumour

Phase II

NCT03522298

KAZIA THERAPEUTICS

DIPG
Highly aggressive childhood brain tumour

Phase I

NCT03696355

St. Jude Children's Research Hospital
ALSAC • Danny Thomas, Founder

Secondary Brain Cancer
(brain cancer that spreads from elsewhere in the body)

Brain Metastases
Cancer that has spread from any primary tumour

Phase II

NCT03994796

NIH NATIONAL CANCER INSTITUTE

Breast Cancer Brain Mets
(combination with Herceptin®)

Phase II

NCT03765983

DANA-FARBER CANCER INSTITUTE

Brain Metastases
(combination with radiotherapy)

Phase I

Memorial Sloan Kettering Cancer Center

Cantrixil

Ovarian Cancer

Platinum-Resistant Ovarian Ca.
(combination with chemotherapy)

Phase I

NCT02903771

KAZIA THERAPEUTICS

Funded by Kazia

Funded Primarily Through Partnerships and External Funding

Funded by Kazia

Kazia has delivered all milestones to date, with multiple data read-outs expected over 6-12 months



Note: forward-looking milestones are forecast and indicative but subject to revision

Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer



Glioblastoma Multiforme

133,000 cases per annum worldwide

Indicative Market Opportunity

US$ 1.5 billion

No clear cause

or strong risk factors

3-4 months

untreated survival

12-15 months

average survival with treatment

Any age, but most common in

60s

Five-year survival

3 – 5%

(breast cancer: 90%)

Sen. John McCain
US politician

Matt Price
ABC journalist

Stan Zemanek
Media personality

Andrew Olle
ABC journalist

Chris O'Brien, AO
Surgeon

KAZIA THERAPEUTICS

Temozolomide is only FDA-approved drug for GBM; it is ineffective in ~65% of cases

Standard of Care ('Stupp Regimen')





~35% of patients respond to temozolomide

Extends overall survival from 15 to 22 months

~65% of patients don't respond to temozolomide

Extends overall survival from 12 to 13 months

GDC-0084 is being developed for the ~65% of newly-diagnosed GBM patients who will not respond to existing chemotherapy with temozolomide

For these patients, there is no effective pharmacological treatment currently available

Source: ME Hegi, A-C Diserens, T Gorlia, et al. (2005). *N Engl J Med* 352:997-1003

Note: Temozolomide is only approved therapy for newly-diagnosed patients; Avastin (bevacizumab) is approved for use in recurrent setting

KAZIA THERAPEUTICS

PI3K class is well-validated, but GDC-0084 is unique in its ability to cross the blood-brain barrier

	Zydelig (idelalisib)	Aliqopa (copanlisib)	Copiktra (duvelisib)	Piqray (alpelisib)	**GDC-0084**
					
	FDA Approved **July 2014** (blood cancers) [accelerated approval] ✓	FDA Approved **September 2017** (blood cancers) [accelerated approval] ✓	FDA Approved **October 2018** (blood cancers) [accelerated approval] ✓	FDA Approved **May 2019** (breast cancer) [accelerated approval] ✓	In phase II human trials under US FDA oversight (brain cancer)
	Does not cross blood-brain barrier ✗	Does not cross blood-brain barrier ✗	Does not cross blood-brain barrier ✗	Does not cross blood-brain barrier ✗	Does cross blood-brain barrier ✓
	Potentially fatal liver toxicity and diarrhoea ✗	Potentially fatal infections ✗	Potentially fatal infections & diarrhoea ✗	Limited toxicities to date ✓	Appears generally safe and well-tolerated thus far ✓

In GDC-0084 phase 1, 7 / 27 patients (26%) showed a ‘metabolic partial response’ on FDG-PET

Pre-Dosing *On GDC-0084* *Pre-Dosing* *On GDC-0084*



Analysis courtesy of Professor Ben Ellingson, UCLA Brain Tumor Imaging Laboratory

Brain cancer represents a significant commercial opportunity for GDC-0084, with limited competition

Path to Market

Glioblastoma

12,500

patients p.a. in the US

~$1.5B+

market opportunity

Expansion Opportunities

Brain Metastases (secondary brain cancer)

Other Adult Primary Brain Cancers

Childhood Brain Cancers

‘Blue Sky’ Potential

Other Cancers with Disordered PI3K Pathway

(*e.g. breast, lung, blood*)

Recent institutional placement leaves the company well funded for next round of data read-outs

Market Capitalisation	~AU$ 30 million
Listing	NASDAQ: KZIA (1:10 ratio) ASX: KZA

Successful placement in October 2019

Current Assets (30 June 2019)	$7.5 million
Institutional Placement (October 2019)	$4.0 million

Funded for multiple value-driving data readouts during 4Q 2019 and 1H 2020

KAZIA THERAPEUTICS

www.kaziatherapeutics.com